Literature DB >> 2543739

Reactivities of polyclonal and monoclonal antibodies raised to the major capsid protein of human papillomavirus type 16.

D Patel1, P S Shepherd, J A Naylor, D J McCance.   

Abstract

Polyclonal and monoclonal antibodies have been raised against a fusion protein containing beta-galactosidase and part of the major capsid protein L1 of the human papillomavirus (HPV) type 16. The polyclonal antibodies cross-reacted with the L1 protein of several HPV types including HPV-1, -2, -6 and -11 when reacted with virus-infected tissue sections, and with HPV-6 and -18 L1 fusion proteins on Western blotting. Monoclonal antibodies against the L1 fusion protein of HPV-16 reacted only with HPV-16 L1 fusion proteins on Western blots and with HPV-16-containing biopsy sections as assessed by in situ DNA-DNA hybridization. These antibodies did not detect HPV-6 L1 protein after Western blotting or in HPV-6-infected tissue sections, although one did react with an HPV-18 fusion protein after Western blotting. The monoclonal antibodies were able to detect HPV-16 antigens in routine formaldehyde-fixed, wax-embedded sections of cervical intraepithelial neoplasia sections. HPV-16 L1 proteins were seen in one-third of biopsies that were positive using the polyclonal cross-reacting antisera. Polyclonal antibodies to fusion proteins containing part of the minor capsid protein L2 of HPV-6 or -16 appeared to be more type-specific as no cross-reactivity was seen when these antibodies were reacted with HPV-1- and -2-infected tissue sections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543739     DOI: 10.1099/0022-1317-70-1-69

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Simultaneous in situ genotyping and phenotyping of human papillomavirus cervical lesions: comparative sensitivity and specificity.

Authors:  A K Graham; C S Herrington; O McGee J
Journal:  J Clin Pathol       Date:  1991-02       Impact factor: 3.411

2.  Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses.

Authors:  L Dillner; P Heino; J Moreno-Lopez; J Dillner
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

3.  An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16.

Authors:  O Jenkins; J Cason; K L Burke; D Lunney; A Gillen; D Patel; D J McCance; J W Almond
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

4.  Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus.

Authors:  C S McLean; M J Churcher; J Meinke; G L Smith; G Higgins; M Stanley; A C Minson
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

5.  Development of type-specific and cross-reactive serological probes for the minor capsid protein of human papillomavirus type 33.

Authors:  C Volpers; M Sapp; C A Komly; P Richalet-Secordel; R E Streeck
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

6.  The discrimination of high-risk HPV types by in situ hybridization and the polymerase chain reaction.

Authors:  C S Herrington; S M Anderson; A K Graham; J O McGee
Journal:  Histochem J       Date:  1993-03

7.  Correlation of HPV antigen and type of genital warts with atypia.

Authors:  B Kumar; R Gupta; S Sehgal
Journal:  Genitourin Med       Date:  1991-04

8.  Human papillomavirus type 16 infection of the cervix: a comparison of differing DNA detection modes and the use of monoclonal antibodies against the major capsid protein.

Authors:  C J Lacey; M Wells; R I Macdermott; P E Gibson
Journal:  Genitourin Med       Date:  1991-04

9.  Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling).

Authors:  Fahad N Almajhdi; Tilo Senger; Haitham M Amer; Lutz Gissmann; Peter Öhlschläger
Journal:  PLoS One       Date:  2014-11-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.